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A low-M freely di~ysable ~dothe~i~ ceil-st~rn~a~~~ angiogenesis factor (ESAF) from unctions 
medium of a mouse lymphoma celi line has previous& been shown to activate latent skin fibrobiast 
pr~ollagen~. Activation comp~able with the maximum that can be achieved with trypsin is obtained 
with chemically undetectable amounts of the factor. We now show that when even smaller amounts of 
ESAF are used heparin is able to ~tentiate its action in this system. The ~elatio~s~~ between this activity 
and the. mechanism of biogenesis, which is itself potentiated by heparin, is discussed. 
ProerMagenase Heparin Angiogenesis 
We have recently reported the extraction of a 
low-M* tumour augiogenesis factor, which induces 
n~v~cul~izatio~ on the chick ~horio~l~ntoic 
membrane (CAM) [l] and stimulates the prolifera- 
tion of cultured capillary endo~e~al cells [2], The 
factor has also been obtained from non-tumour 
sources, and is called endothelial cell stimulating 
angiogenesis factor (ESAF). We have also shown 
that ESAF activates skin fibroblast pr~olla~~e 
[3]. A unifying mechanism of action for a factor 
which is able to induce both endotherm cell pro- 
liferation and directional growth, which are pro- 
perties of a~ogenic substances [4], is difficult to 
understand. However, the ability of ESAF to ac- 
tivate a latent form of collagenase may be a highly 
relevant aspect. 
It has been observed that mast cells accumulate 
at the leading tip of growing capillaries and it has 
been suggested that angiogenesis does not occur 
unless these ceils are present. Heparin, a mast cell 
product, potentiates the effect of other angiogenic 
factors [S] as well as our own (unpub~shed) obser- 
vations OR the chick CAM bioassay, For this 
reason we have studied the effect of heparin on 
FBAF activation of skin fibroblast pr~ollagenase. 
ESAF was prepdred from medium comiitioned 
by a cloned mouse lymphoma cell line 161. The 
angiogenesis factor was freely dialysable and 
eluted from a gel fil~ation column (Bio-Gel P2,44 
x 4.4 cm run in lo%, v/v, props-2~ol~water, 
45 ml/h) in a position corresponding to a Mr of 
300-600. 
Procollagenase was prepared from serum-free 
human skin fibroblast conditioned medium using a 
modification of the method in 17 1. Serum-free con- 
ditioned medium was applied to a SephacrylS200 
column (80 x 2.5 cm) and eluted with Tris-WC1 
buffer (PH 7.6) containing 0.2 M NaGl and 
0.01 M CaGL. The enzyme was activatable by 
Mersalyl {table 1) and the met~loprotein~e nature 
of the preparation was confirmed by the EDTA in- 
hibition of the Mersalyl and ESAF activated pro- 
enzyme (table 1). Analysis of the degradation pro- 
ducts from the Gore-cat~ysed hydrolysis of 
Type-I collagen by SDS-polyacrylamide gel elec- 
trophoresis revealed the $95 and 3/o collagen 
fragments ~h~a~teristic of the action of mam- 
malian collagenase 181. 
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Table 2 
Effect of fractionated heparin on activation of skin 
fibroblast procollagenase 
Assay mixture peg Type-I collagen 
degraded/l6 h
Enzymea 0 
+ mersalyl 11.7 f 0.2 
-I- Hi 0.25 f 0.05 
+ Hz 0.3 + 0.04 
+ ESAFC 9.1 f 0.6 
+ ESAF + HI 8.6 f 0.4 
+ ESAF + Hz 14.2 * 0.7 
Hlb 0 
HZb 0 
* Skin fibroblast procollagenase 
b Hr = &fr 35000 heparin, HZ = Mr 16000 heparin 
’ ESAF used in this experiment was a different batch 
from that used for results in table 1 
Controls and EDTA blanks have been subtracted from 
the results 
it is not clear what the high-M, component 
represents, although our results show that it con- 
tains ~ycos~inoglycan. 
We have previously reported that ESAF ac- 
tivates a skin fibroblast procollagenase [3]. Here 
we have shown that heparin potentiates the action 
of limiting amounts of ESAF. Fu~hermore, 
heparin alone gives slight activation of pro- 
collagenase whereas, like ESAF, it has no effect on 
the fully activated enzyme. The mild activating ef- 
fect of heparin on mouse bone collagenase has 
been explained in [14,15] as being due to binding 
of the heparin to both collagen substrate and to 
collagenase, thereby increasing the concentration 
of enzyme at the surface of the fibril. However, it 
is unclear from their work whether the effect of the 
heparin was to activate a latent mouse bone col- 
lagenase or to enhance the activity of a previously 
activated enzyme. It would seem unlikely that the 
effect of heparin in our system is due to this 
mechanism as heparin alone has no effect on the 
fully active enzyme. Rather, the most significant 
effect of heparin is its ability to potentiate, in a 
synergistic manner, the activating effect of limiting 
amounts of ESAF on procollagenase, As mention- 
ed above, heparin binds to both enzyme and 
substrate and we have shown that ESAF binds 
strongly to collagen. The significance of this obser- 
vation is being investigated, 
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The mechanism of action of tumour 
angiogenesis factor is unclear. The requirements 
for an angiogenesis factor are that it can stimulate 
endothelial cells to proliferate and also cause them 
to migrate towards the source of the factor. The 
directional effect could be partially explained by 
the activation by angiogenesis factors of pro- 
collagenase present in the connective tissue matrix 
[3]. Since the collagen in the intracellular matrix is 
in a fibrillar form, digestion would be limited, as 
the insoluble collagen is a relatively poor substrate 
for the enzyme [ 161. The appearance of mast cells 
during new capillary growth with their ability to 
release heparin has been described [5] and heparin 
has been shown to potentiate angiogenesis on the 
chick CAM [5]. An explanation for this observa- 
tion might be that heparin could potentiate the ac- 
tion of ESAF locally resulting in a ‘concentration’ 
of collagenolytic activity. This in turn could lead to 
the formation of channels in the matrix. These 
channels would provide a route along which en- 
dothelial cells could migrate towards the source of 
angiogenesis factor. However, the question re- 
mains what the stimulus is for the appearance of 
mast cells? The overall process of angiogenesis 
which encompasses the initiation, growth and con- 
trol of new blood vessel growth must involve a 
number of steps, possibly arranged to form a 
cascade of reactions. It is obvious that con- 
siderably more information must be obtained 
before the mechanism of angiogenesis is fully ex- 
plained. However, the results presented here sug- 
gest that one effect of heparin in the process of 
angiogenesis may be to modulate ESAF activation 
of a procollagenase. 
It would also be possible that a basement 
membrane-degrading enzyme, synthesized and 
secreted by endothelial cells themselves, could be 
activated in the same manner. Preliminary work in 
our laboratory has shown that ESAF is able to ac- 
tivate a partially purified basement membrane- 
degrading enzyme. We are currently studying this 
effect together with the possibility that heparin 
might also potentiate this activity. 
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